Madurella mycetomatis Is Highly Susceptible to Ravuconazole
SA Ahmed, W Kloezen, F Duncanson… - PLoS neglected …, 2014 - journals.plos.org
The current treatment of eumycetoma utilizing ketoconazole is unsatisfactory because of
high recurrence rates, which often leads to complications and unnecessary amputations,
and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is
required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum
triazole currently being developed for the treatment of Chagas disease. E1224 is a prodrug
that is rapidly converted to ravuconazole. Plasma levels of E1224 are low and transient, and …
high recurrence rates, which often leads to complications and unnecessary amputations,
and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is
required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum
triazole currently being developed for the treatment of Chagas disease. E1224 is a prodrug
that is rapidly converted to ravuconazole. Plasma levels of E1224 are low and transient, and …
[PDF][PDF] Madurella mycetomatis is highly susceptible to ravuconazole
WWJ Sande - 2014 - pure.uva.nl
The current treatment of eumycetoma utilizing ketoconazole is unsatisfactory because of
high recurrence rates, which often leads to complications and unnecessary amputations,
and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is
required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum
triazole currently being developed for the treatment of Chagas disease. E1224 is a prodrug
that is rapidly converted to ravuconazole. Plasma levels of E1224 are low and transient, and …
high recurrence rates, which often leads to complications and unnecessary amputations,
and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is
required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum
triazole currently being developed for the treatment of Chagas disease. E1224 is a prodrug
that is rapidly converted to ravuconazole. Plasma levels of E1224 are low and transient, and …
以上显示的是最相近的搜索结果。 查看全部搜索结果